All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Innovative Agreements Framework
Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.
2022 Code of Ethical Practices
Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.
Research Note: Oncology Clinical Trials: Canada Within the International Context
Clinical trials provide Canadian oncology patients with earlier access to new, innovative cancer treatments. But changes pending to the PMPRB will make the Canadian pharmaceutical market less attractive for investment.
Cost Drivers: Analysis of Private Drug Plans in Canada 2021
The 2021 Cost Drivers report highlights the consistent annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
The Canadian Research and Development Pharmaceutical Sector
StatsCan examines the economic footprint made by Canada’s research and development pharmaceutical sector in 2018, including the contributions of Innovative Medicines Canada.
Making Canada an International Life Sciences Leader
The COVID-19 pandemic has graphically demonstrated the need for a better life sciences environment in Canada. This document outlines the industry’s recommendations for building a thriving sector.
Drug Reimbursement Timeline by Stages 2019-2020
Source: IMC analysis of IQVIA International Reimbursement Comparison data and IQVIA Public Reimbursement data. CADTH and provincial listing timelines are for drugs with a pCPA LOI in the respective year. Provincial Listing is the average time from pCPA completed negotiation to provincial listing dates for drugs with a pCPA LOI. CADTH, pCPA, and provincial listing timelines are arithmetic averages.
2016-2019 Analysis of Private Drug Claim Cost Drivers
The 2016–2019 Cost Drivers report highlights annual cost growth in the Canadian private drug benefits market and outlines factors that contribute to price increases.
